International, Peer Reviewed, Open Access Journal

Cancer Clinics Journal
(ISSN: 2689-9566)

Submit Manuscript

Cancer Clinics Journal

Cancer Clinics Journal (ISSN: 2689-9566) is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Cancer Clinics Journal (ISSN: 2689-9566) is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Open Access - Cancer Clinics Journal

Editorial Board

Soldano Ferrone - Cancer Clinics Journal

Soldano Ferrone

Harvard Medical School
United States

Girijesh Kumar Patel - Cancer Clinics Journal

Girijesh Kumar Patel

University of South Alabama
United States

Yongqing Liu - Cancer Clinics Journal

Yongqing Liu

University of Louisville
United States

Mohammad Aslam Khan - Cancer Clinics Journal

Mohammad Aslam Khan

University of South Alabama-Mitchell Cancer Institute
United States

Maria Angelica Cortez - Cancer Clinics Journal

Maria Angelica Cortez

The University of Texas MD Anderson Cancer Center
United States

Hexin Chen - Cancer Clinics Journal

Hexin Chen

University of South Carolina
United States

Shanta M Messerli - Cancer Clinics Journal

Shanta M Messerli

Sanford Health
United States

Susana Maria Campos - Cancer Clinics Journal

Susana Maria Campos

Dana-Farber Cancer Institute
United States

Randa A. El-Zein - Cancer Clinics Journal

Randa A. El-Zein

Houston Methodist Hospital Houston
United States

Peter C. Hu - Cancer Clinics Journal

Peter C. Hu

The University of Texas MD Anderson Cancer Center
United States

Sanjeev K. Srivastava - Cancer Clinics Journal

Sanjeev K. Srivastava

University of South Alabama
United States

Giuliano Di Pietro - Cancer Clinics Journal

Giuliano Di Pietro

Department of Cancer Epidemiology , H Lee Moffitt Cancer Center, Tampa
United States

Articles

Cancer Clin J. 2022;3(1):CCJ-03-1015 | Open Access

Conquering the Bottlenecks in Cancer Therapeutics via Drug Repurposing of Antimalarials Drugs: A Review

Shreelekha Naikar, Shafina Siddiqui, Shine Devarajan, Soumya Basu, Jyotirmoi Aich

Chemotherapy and radiation therapy are some of the known treatments available for treating cancer. Unfortunately, over the years patients have developed chemo resistance to the drugs. To overcome this resistance, drug repurposing is considered an effective and alternative strategy for cancer therapy. Different antimalarial drugs have exhibited anticancer properties in various cancer types. In this review, the anticancer activity of ... Read more

REVIEW ARTICLE Updated Dec 19, 2022   PDF

Cancer Clin J. 2022;3(1):CCJ-03-1014 | Open Access

To Identify Key HCC-Related Genes and Prognostic Models of HBV Infection Based on Protein Interaction Network

Qingxiu Li and Changzhu Duan

The occurrence of Hepatitis B Virus-induced Hepatocellular Carcinoma (HBV-HCC) is a complex process of multi-gene and multi-step interaction, in which the synergistic effect of various cancer-promoting mechanisms accelerates the disease evolution from inflammation to tumorigenesis. In this study, first, genes encoding human proteins associated with HBV-HCC were screened from the MEDLINE literature. Based on the Protein-Protein Interaction network (PPI) in ... Read more

RESEARCH ARTICLE Updated Nov 22, 2022   PDF

Cancer Clin J. 2022;3(1):CCJ-03-1013 | Open Access

Liver Failure Letrozole-Induced, Case Report and Review of the Literature

De Jesus Ramos E, Miyagui Adame SM, Ruiz Cruz S, Rodriguez JA, Lino Silva S, Cabrera Galeana P and Arce Salinas CH

Goals: Letrozole is an aromatase inhibitor widely used as an anti-estrogenic therapy for breast cancer in patients expressing estrogen and/or progesterone receptors. There is currently no data that places it as a potentially hepatotoxic drug. So far, this is the first reported case of Letrozole-induced liver failure in a woman with breast cancer, so we consider the publication of ... Read more

CASE REPORT Updated Jul 08, 2022   PDF

Cancer Clin J. 2020;2(1):CCJ-02-1012 | Open Access

The Effect of Acupuncture on Obstructive Jaundice Secondary to Metastatic Gastric Cancer after Failure of Percutaneous Transhepatic Cholangiography and Drainage: A Case Report

Qi Min, Ting Chen and Yongjie Zhang

Obstructive jaundice is a rare complication of gastric cancer and portends poor prognosis. Percutaneous biliary drainage or implantation of biliary stents are commonly used treatment. In our case who was afflicted with biliary obstruction secondary to metastatic gastric cancer, Percutaneous Transhepatic Cholangiography and Drainage (PTCD) was performed, however, the efficacy was not optimistic, as shown by sustained elevation of serum ... Read more

CASE REPORT Updated Nov 02, 2020   PDF

Cancer Clin J. 2020;2(1):CCJ-02-1011 | Open Access

Bladder Cancer New Biomarkers in Liquid Biopsies

Gil Falcão, João Vasco Barreira, Anuraj Parmanande, Cabrita Carneiro and Luís Campos Pinheiro

Bladder cancer is one of the most common neoplasia in men in the developed countries. Diagnosis and surveillance are made by bladder examination through cystoscopy making this one of the most expensive on cost/patient. After tumor removal, clinical staging is important for prognosis and treatment decision as non-muscle invasive (Ta and T1) and invasive (T2+) are treated in a ... Read more

RESEARCH ARTICLE Updated Aug 25, 2020   PDF